Antibody

25개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved25 programs
AntibodyCurated CoreFDABristol Myers SquibbApproved

nivolumab (Opdivo, BMS-936558)

Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1280Status Approved
AntibodyCurated CoreFDAAstraZenecaApproved

durvalumab (Imfinzi, MEDI4736)

NSCLC (Stage III consolidation), SCLC, biliary tract, HCC · PD-L1

#PD-L1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 750Status Approved
AntibodyCurated CoreFDARocheApproved

atezolizumab (Tecentriq, MPDL3280A)

NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others · PD-L1

#PD-L1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 693Status Approved
AntibodyLimited DatastaleAstraZenecaPhase 3

Durvalumab (MEDI4736, MEDI4736 (Durvalumab))

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase3#Popular#monoclonal-antibody+3
Trials 94Status Active
AntibodyLimited DatastaleAstraZenecaPhase 3

durvalumab (Imfinzi, MEDI4736, MEDI4736 (Durvalumab) + Tremelimumab)

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Malignancies

#AdvancedSolidMalignancies#Antibody#Phase3#Popular#monoclonal-antibody+2
Trials 56Status Recruiting
AntibodyLimited DatastaleRegeneron PharmaceuticalsPhase 2

Fianlimab (Fianlimab)

Ovarian Cancer; Fallopian Tube Cancer · NSCLC

#NSCLC#Antibody#Phase2#monoclonal-antibody#OvarianCancer+3
Trials 39Status Recruiting
AntibodyLimited DatastaleTang-Du HospitalPhase 2

Adebrelimab combined with Apatinib (Adebrelimab combined with Apatinib)

SCLC · SCLC

#SCLC#Antibody#Phase2#monoclonal-antibody#Tang-Du
Trials 30Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 1

durvalumab (Imfinzi, Administration of ceralasertib and durvalumab)

Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer · Adv Solid Malig - H&N SCC, ATM Pro / Def

#AdvSolidMalig-HNSCCATMProDef#Antibody#Phase1#monoclonal-antibody#AdvSolidMalig-HNSCC+3
Trials 12Status Recruiting
AntibodyLimited DatastaleBeiGenePhase 1

atezolizumab (Tecentriq, Tislelizumab，atezolizumab or sugemalimab)

NSCLC · NSCLC

#NSCLC#Antibody#Phase1#monoclonal-antibody#BeiGene
Trials 4Status Recruiting
AntibodyLimited DatastaleAbbViePhase 1

Cofetuzumab Pelidotin (Cofetuzumab Pelidotin)

Cancer; Non-small Cell Lung Cancer (NSCLC) · Cancer

#Cancer#Antibody#Phase1#monoclonal-antibody#Non-smallCellLungCancerNSCLC+1
Trials 2Status Discontinued
AntibodyLimited DatastaleHenan Cancer HospitalPhase 2

durvalumab (Imfinzi, Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer)

SCLC, Extensive Stage · SCLC, Extensive Stage

#SCLCExtensiveStage#Antibody#Phase2#monoclonal-antibody#SCLC+2
Trials 1Status Active
AntibodyLimited DatastaleXinqiao Hospital of ChongqingPhase 2

Benmelstobart combined with Bevacizumab and chemotherapy (Benmelstobart combined with Bevacizumab and chemotherapy)

NSCLC Stage IV Without EGFR/ALK Mutation · EGFR

#EGFR#Antibody#Phase2#monoclonal-antibody#NSCLCStageIVWithoutEGFR+2
Trials 1Status Recruiting
AntibodyLimited DatastaleBrightPath BiotherapeuticsPhase 2

pembrolizumab (Keytruda, GRN-1201 + Pembrolizumab)

Metastatic NSCLC · Metastatic NSCLC

#MetastaticNSCLC#Antibody#Phase2#monoclonal-antibody#BrightPath
Trials 1Status Discontinued
AntibodyLimited DatastaleBristol-Myers SquibbPreclinical

nivolumab (Opdivo, Immuno-oncology-based therapy, excluding nivolumab-based regimens, Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy)

Non-small Cell Lung Cancer (NSCLC) · Non-small Cell Lung Cancer (NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Preclinical#monoclonal-antibody#Bristol-Myers
Trials 1Status Recruiting
AntibodyLimited DatastaleY-mAbs TherapeuticsPhase 2

Nivatrotamab (Nivatrotamab)

SCLC · SCLC

#SCLC#Antibody#Phase2#monoclonal-antibody#Y-mAbs
Trials 1Status Discontinued
AntibodyLimited DatastaleLG ChemPhase 1

atezolizumab (Tecentriq, Phase 1b: LB-LR1109 and Atezolizumab)

Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC) · Non-small Cell Lung Cancer(NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Phase1#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

QLS5132; Bevacizumab (QLS5132; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#monoclonal-antibody#Non-smallCellLungCancerNSCLC+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

QLS5132; Platinum; Bevacizumab (QLS5132; Platinum; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#monoclonal-antibody#Non-smallCellLungCancerNSCLC+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAmsterdam UMC, location VUmcPhase 2

pembrolizumab (Keytruda, SABR + pembrolizumab)

NSCLC, Stage I · NSCLC, Stage I

#NSCLCStageI#Antibody#Phase2#monoclonal-antibody#NSCLC+2
Trials 1Status Active
AntibodyLimited DatastaleSanofiPhase 2

Tusamitamab ravtansine (SAR408701, SAR408701 (Tusamitamab ravtansine))

Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) · Non-squamous Non-small-cell Lung Cancer

#Non-squamousNon-small-cellLungCa#Antibody#Phase2#monoclonal-antibody#Sanofi
Trials 1Status Discontinued

1 / 2 pages

← PreviousNext →